Data Show U.S. Trade Deals Not Spurring Increases In Drug Prices, Could Have Implications For TPP
Council on Foreign Relations: The Long Fight Over Trade and Medicines
In an online interactive, Thomas J. Bollyky, senior fellow for global health, economics, and development at CFR, examines new data suggesting U.S. trade deals are not be spurring a “discernable trend toward more expensive original or branded versions of medicines and away from cheap unbranded generic drugs, either as a matter of volume or spending. … An explanation of the potential reasons for the (as of yet) limited effects of recent U.S. trade deals on medicines and its implications for the TPP appears in Foreign Affairs…” (3/24).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.